Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00035
|
|||||
| Drug Name |
Axitinib
|
|||||
| Synonyms |
AG 013736; AG-013736; AG-013736, Axitinib; AG-13736; AG013736; Axitinib (VEGFR inhibitor); N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Advanced renal cell carcinoma [ICD11: 2C90] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H18N4OS
|
|||||
| Canonical SMILES |
CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
|
|||||
| InChI |
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
|
|||||
| InChIKey |
RITAVMQDGBJQJZ-FMIVXFBMSA-N
|
|||||
| CAS Number |
CAS 319460-85-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 386.5 | Topological Polar Surface Area | 96 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
4.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
114525306
, 118844929
, 11972112
, 123098392
, 124756928
, 124950168
, 125163735
, 126621224
, 126647931
, 126666999
, 131465099
, 134339005
, 134964394
, 135236613
, 135697692
, 135727420
, 136368079
, 136920276
, 137006067
, 137255399
, 140075950
, 144075334
, 144115649
, 144207146
, 14804960
, 152042317
, 152258076
, 152344032
, 160645509
, 160646915
, 162011700
, 162037379
, 162112056
, 162164950
, 162170729
, 163395346
, 164041895
, 164833257
, 17397371
, 26683791
, 43041647
, 51067393
, 56374259
, 56459367
, 57370217
, 71821495
, 85246173
, 92718920
, 99004612
, 99431770
|
|||||
| ChEBI ID |
CHEBI:66910
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Axitinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.